Creso Pharma : Appendix 4E and Annual Report to Shareholders

For personal use only

CRESO PHARMA LIMITED

ACN 609 406 911

Appendix 4E for the

Year Ended 31 December 2021

Final Report

For the year ended 31 December 2021, previous corresponding period is 31 December 2020.

For personal use only

Results for announcement to the market		2021	2020
	Up/(down)	$	$
Revenue from ordinary activities	154.0%	6,218,337	2,447,761
Loss from ordinary activities after tax attributable to members	(6.3)%	(30,030,967)	(32,036,866)
Loss from ordinary activities attributable to members	(6.3)%	(30,030,967)	(32,036,866)

Refer to the Operating and Financial Review in the Annual Report for further information on the results.

Dividends

No dividends have been paid or declared by the Group since the end of the previous financial year (2020: Nil).

No dividend is recommended in respect of the current financial year (2020: Nil).
Net Tangible Assets Per Security	2021	2020
Net Tangible Assets Per Security (cents)	1.51	1.37

Audit Report

This report is based on the consolidated financial statements for the year ended 31 December 2021 which have been audited by BDO Audit Pty Ltd. The audit report in the consolidated financial statements contains an emphasis of matter with respect to material uncertainty over going concern.

Additional Appendix 4E disclosure requirements are included in the following pages.

Signed on behalf of the directors

James Ellingford

EXECUTIVE CHAIRMAN

28 February 2022

2

For personal use only

CRESO PHARMA LIMITED

ACN 609 406 911

Annual Report for the

Year Ended 31 December 2021

Creso Pharma Limited - Annual Report 2021

Annual Report

For the year ended 31 December 2021

Contents

For personal use only

About Creso	3
Corporate Directory	4
Chairman's Address	5
CEO's Report	7
Directors' Report	8
Remuneration Report	25
Auditor's Independence Declaration	38
Consolidated Statement of Profit or Loss and Other Comprehensive Income	39
Consolidated Statement of Financial Position	40
Consolidated Statement of Changes in Equity	41
Consolidated Statement of Cash Flows	42
Notes to the Consolidated Financial Statements	43
Directors' Declaration	86
Independent Auditor's Report	87
Shareholder Information	92

2 | P a g e

Creso Pharma Limited - Annual Report 2020

For personal use only

About Creso Pharma

Creso Pharma brings the best of cannabis to better the lives of people and animals.

Creso brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products. It develops cannabis and hemp-derived therapeutic, nutraceutical, and lifestyle products with wide patient and consumer reach for human and animal health.

Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland.

Creso has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.

Creso is developing products in four key areas:

Creso has operations in Switzerland, Canada and Australia.

www.CresoPharma.com

3 | P a g e